Printer Friendly

TransEnterix reports divestiture of Senhance Surgical System in Germany.

M2 EQUITYBITES-February 24, 2017-TransEnterix reports divestiture of Senhance Surgical System in Germany

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Medical device company TransEnterix Inc (NYSE MKT:TRXC) revealed on Thursday the completion of the first sale of the Senhance Surgical System in Germany for an undisclosed amount.

Under the terms of an agreement, the company has divested the Senhance Surgical System to St. Marien-Krankenhaus Siegen, a large multi-specialist hospital.

St. Marien-Krankenhaus Siegen, which is part of an independent, integrated health group that treats patients throughout the federal states of North Rhine-Westphalia and Rhineland-Palatinate, will now establish a robotic surgical programme that will initially be focused on general and gynecologic surgery.

The Senhance Surgical Robotic System is reportedly a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the US.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 24, 2017
Words:178
Previous Article:National Storage Affiliates announces dividend of USD0.24 per share for Q1 2017.
Next Article:Genesis HealthCare incurs lower US GAAP net loss of USD64.0m for fiscal 2016.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters